Recipharm AB (RECI B):企業の財務・戦略的SWOT分析

◆英語タイトル:Recipharm AB (RECI B) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1634
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Recipharm AB (RECI B) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The company’s manufacturing services include contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, solid dose, sterile products, besides clinical trial materials including APIs and other drugs. Recipharm’s development and technology services supports customers from initial product concept to the approved commercial pharmaceutical drug. It includes services such as raw material supply, formulation, validated analytical methods, among others. The company operates in the UK, Germany, Spain, Italy, Sweden, France, Portugal, India, Israel and the US. Recipharm is headquartered in Stockholm, Sweden.

Recipharm AB Key Recent Developments

Mar 06,2020 Recipharm completes delisting of Consort Medical
Mar 06,2020 Recipharm notes an increased demand for Chloroquine Phosphate

Feb 20,2020 Recipharm publishes report for the fourth quarter and full year 2019
Feb 07,2020 Recipharm announces that Consort Medical applies for delisting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Recipharm AB – Key Facts
Recipharm AB – Key Employees
Recipharm AB – Key Employee Biographies
Recipharm AB – Major Products and Services
Recipharm AB – History
Recipharm AB – Company Statement
Recipharm AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Recipharm AB – Business Description
Business Segment: D&T
Overview
Performance
Business Segment: MFG-SI
Overview
Performance
Business Segment: MFG-SO
Overview
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: India
Performance
Geographical Segment: Italy
Performance
Geographical Segment: Other
Performance
Geographical Segment: Portugal
Performance
Geographical Segment: Spain
Performance
Geographical Segment: Sweden
Performance
Geographical Segment: UK
Performance
Recipharm AB – Corporate Strategy
Recipharm AB – SWOT Analysis
SWOT Analysis – Overview
Recipharm AB – Strengths
Recipharm AB – Weaknesses
Recipharm AB – Opportunities
Recipharm AB – Threats
Recipharm AB – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Recipharm AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 06, 2020: Recipharm completes delisting of Consort Medical
Mar 06, 2020: Recipharm notes an increased demand for Chloroquine Phosphate
Feb 20, 2020: Recipharm publishes report for the fourth quarter and full year 2019
Feb 07, 2020: Recipharm announces that Consort Medical applies for delisting
Feb 05, 2020: Consort Medical becomes part of the Recipharm Group
Dec 09, 2019: Recipharm invests in its US inhalation development service
Nov 18, 2019: Recipharm to communicate new financial targets on Capital Markets Day
Nov 14, 2019: Recipharm joins the AMR Industry Alliance
Nov 07, 2019: Recipharm publishes its interim report January – September 2019
Nov 06, 2019: Recipharm expands Indian injectable dosage form capabilities through new partnership
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Recipharm AB, Key Facts
Recipharm AB, Key Employees
Recipharm AB, Key Employee Biographies
Recipharm AB, Major Products and Services
Recipharm AB, History
Recipharm AB, Other Locations
Recipharm AB, Subsidiaries
Recipharm AB, Key Competitors
Recipharm AB, Ratios based on current share price
Recipharm AB, Annual Ratios
Recipharm AB, Annual Ratios (Cont...1)
Recipharm AB, Annual Ratios (Cont...2)
Recipharm AB, Interim Ratios
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Recipharm AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Recipharm AB, Performance Chart (2015 - 2019)
Recipharm AB, Ratio Charts
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Recipharm AB (RECI B):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Beactica AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Beactica AB (Beactica) is a drug discovery company develops a pipeline of novel and mechanistically defined small molecule therapeutics. The company offers wide range of services such as fragment-based lead generation, kinetic and mechanistic characterization of inhibitors, extended rate ana …
  • Fujifilm Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Fujifilm Corp (Fujifilm), a subsidiary of Fujifilm Holdings Corporation, is a provider of imaging and information solutions. The company’s product portfolio encompasses color films, optical devices, digital cameras, photofinishing equipment and color paper, chemicals and services for photofi …
  • U.S. Energy Corp (USEG):企業の財務・戦略的SWOT分析
    Summary U.S. Energy Corp (US Energy) is an oil and gas company that offers exploration, development and production of oil and natural gas properties. The company provides maintenance of mineral properties. It operates its oil and gas prospects located in the Williston Basin of North Dakota, the Eagl …
  • The Credit Mutuel-Cic Group:企業の戦略・SWOT・財務分析
    The Credit Mutuel-Cic Group - Strategy, SWOT and Corporate Finance Report Summary The Credit Mutuel-Cic Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Synchrony Financial:企業の戦略・SWOT・財務情報
    Synchrony Financial - Strategy, SWOT and Corporate Finance Report Summary Synchrony Financial - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Glenmede Corporation:企業の戦略・SWOT・財務情報
    Glenmede Corporation - Strategy, SWOT and Corporate Finance Report Summary Glenmede Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Taageer Finance Company SAOG (TFCI):企業の財務・戦略的SWOT分析
    Taageer Finance Company SAOG (TFCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Enerjisa Enerji AS (ENJSA):企業の財務・戦略的SWOT分析
    Enerjisa Enerji AS (ENJSA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Nottingham Building Society:企業の戦略・SWOT・財務情報
    Nottingham Building Society - Strategy, SWOT and Corporate Finance Report Summary Nottingham Building Society - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Micron Technology Inc:戦略・SWOT・企業財務分析
    Micron Technology Inc - Strategy, SWOT and Corporate Finance Report Summary Micron Technology Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • United Natural Foods Inc:企業の戦略・SWOT・財務分析
    United Natural Foods Inc - Strategy, SWOT and Corporate Finance Report Summary United Natural Foods Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • High Peak Royalties Ltd (HPR):企業の財務・戦略的SWOT分析
    High Peak Royalties Ltd (HPR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Pear Therapeutics Inc:企業の製品パイプライン分析2018
    Summary Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive …
  • Blueprint Medicines Corp (BPMC)-医療機器分野:企業M&A・提携分析
    Summary Blueprint Medicines Corp (Blueprint) is a biotechnology company that develops drugs for the treatment of cancers. The company discovers selective kinase inhibitors for genomically defined cancer subsets. Its pipeline products include BLU-285, for treatment resistant gastrointestinal stromal …
  • Kingfisher Plc:企業の戦略・SWOT・財務情報
    Kingfisher Plc - Strategy, SWOT and Corporate Finance Report Summary Kingfisher Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • VSTECS Holdings Ltd:企業の戦略・SWOT・財務情報
    VSTECS Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary VSTECS Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Abu Dhabi Commercial Bank P.J.S.C.:戦略・SWOT・企業財務分析
    Abu Dhabi Commercial Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report Summary Abu Dhabi Commercial Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Verily Life Sciences LLC-医療機器分野:企業M&A・提携分析
    Summary Verily Life Sciences LLC (Verily), formerly known as Google Life Sciences LLC, a subsidiary of Alphabet Inc is a life sciences research and engineering organization which develops tools for prevention, detection, and management of diseases. The company develops tools for various projects, su …
  • Aviva plc:企業のM&A・事業提携・投資動向
    Aviva plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Aviva plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • North Asia Strategic Holdings Limited
    North Asia Strategic Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary North Asia Strategic Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆